We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
3
0 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
2012
Completed
1
33.3%
Terminated
Unknown
No approval data available
- Revive Therapeutics is conducting an ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure in collaboration with Defence R&D Canada – Suffield Research Centre. - The study focuses on evaluating pharmacological compounds that may mitigate nerve agent-induced brain injury, with final findings pending authorization from the Canadian Department of National Defence agency. - Revive Therapeutics is a specialty life sciences company that prioritizes drug development efforts to leverage FDA regulatory incentives including Emergency Use Authorization and Breakthrough Therapy designations. - The company is also exploring Bucillamine for long COVID treatment while advancing development programs for Psilocybin and molecular hydrogen therapeutics.
